French drug maker Sanofi says it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays.
Germany-based BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sanofi statement Wednesday.
The company did not reveal financial details of the agreement, according to The Associated Press.
The French government has been pressing Sanofi to use its facilities to help make rival vaccines, given high demand and problems with supplies of the few vaccines that are already available.
Sanofi and British partner GlaxoSmithKline will start a new phase-2 trial of their COVID-19 vaccine next month, Sanofi said.
The two companies said last month that their vaccine won’t be ready until late 2021 because the shot’s effectiveness in older people needed to be improved.
